Swine Flu Virus Hits the Markets

Los Angeles, CA, April 29, 2009 --( Shares of niche makers of antiviral products and vaccines saw shares rocket in early trading Monday on news that the world could be facing a global pandemic of the swine flu virus.

Concerns about the growing health crisis helped boost drug stocks for Biota Holdings Ltd., with U.S.-traded shares shooting up over 600%. Australia-based Biota receives royalties on a leading flu-fighting agent, Relenza, which is marketed by GlaxoSmithKline PLC.

Also gaining at least 40% were Generex Biotechnology Corp., BioCryst Pharmaceuticals, Novavax Inc. and Hemispherx Biopharma Inc.

Hemispherx Biopharma had additional good news for its share holders when it announced it had received notice of an Annual Report prepared by a Director of the National Institute of Infectious Diseases to the governing organization of the Japanese Ministry of Health reporting a series of successful preclinical studies in new pandemic vaccines which rely critically on Ampligen an experimental therapeutic for efficacy.

In February Hemispherx Biopharma had received a letter from the Food and Drug Agency indicating that the originally scheduled Prescription Drug User Fee Act ("PDUFA") date on the Ampligen® (Poly I:Poly C12U) New Drug Application (NDA) would be extended by three months "in order to provide time for a full review of the submission." Additional data were received by the FDA within 3 months of the user fee goal date.

A complete list of upcoming FDA approval decisions and Clinical Trials updates for Hemispherx Biopharma and others is available at


About BiomedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to BiomedReports.Com ( )

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
Mike Havrilla